ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COX inhibitors"

  • Abstract Number: L08 • ACR Convergence 2024

    A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee

    Limin Ren1, Wenjie Zheng2, Zhenpeng Guan3, Yang Zhang4, Zeyu Huang5, Tong Li6, Yuwei Peng7, Qiuli Wu8, Wei Gou9, Wei Zhao10, Pengyan Qiao11, Xiaoli Pan12 and Guang-Liang Jiang13, 1Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, 2Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, 3Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, 4Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, 5West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, 6Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, 7PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, 8Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, 9Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, 10Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, 11Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, 12Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, 13Xgene Pharmaceutical, Lexington, MA

    Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
  • Abstract Number: 1476 • ACR Convergence 2024

    Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis

    Mark Hwang1, Seokhun Kim2, Shervin Assassi3, Joyce Samuel4, Charles Green2, Jon Tyson4 and John Reveille5, 1Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, 2UTHealth Houston, Houston, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4UTHealth Houston, Houston, TX, 5UTHealth Houston Division of Rheumatology, Houston

    Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line pharmacological treatment for Axial Spondyloarthritis (axSpA), yet individual responses to different NSAIDs vary significantly. This study aims…
  • Abstract Number: 1831 • ACR Convergence 2022

    Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)

    Judith Boice1, Travis Helm1, Maria Bermudez2, Mark Corrigan1 and Bradford Sippy1, 1Tremeau Pharmaceuticals, Inc, Concord, MA, 2Clinical Pharmacology of Miami, LLC, Miami, FL

    Background/Purpose: TRM-201 (rofecoxib) is a cyclooxygenase-2 (COX-2) selective inhibitor being developed for the treatment of hemophilic arthropathy (HA) and acute migraine. Previously marketed as VIOXX,…
  • Abstract Number: 0546 • ACR Convergence 2022

    COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine over Two Years in Patients with Ankylosing Spondylitis (CONSUL): An Open-Label, Randomized Controlled, Multicenter Trial

    Fabian Proft1, Bukrhard Muche2, valeria Rios-Rodriguez3, Murat Torgutalp4, Mikhail Protopopov5, Joachim Listing6, Maryna Verba7, Jan Brandt-Juergens8, Uta Kiltz9, Maren Sieburg10, Swen Jacki11, Joachim Sieper4 and Denis Poddubnyy1, 1Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Charité University Hospital, CCM, Berlin, Germany, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Charité - Universitätsmedizin, Berlin, Berlin, Germany, 5Charité Universitätsmedizin Berlin, Berlin, Germany, 6German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany, 7Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 8Rheumatologische Schwerpunktpraxis, Berlin, Germany, 9Rheumazentrum Ruhrgebiet, Herne, Germany, 10Rheumatologische Facharztpraxis, Magdeburg, Germany, 11Rheumatologische Schwerpunktpraxis, Tübingen, Germany

    Background/Purpose: There is some evidence that NSAIDs, in particular celecoxib (CEL), might possess not only symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS),…
  • Abstract Number: 1751 • ACR Convergence 2022

    Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management

    Judith Boice, Mark Corrigan and Bradford Sippy, Tremeau Pharmaceuticals, Inc, Concord, MA

    Background/Purpose: Traditional NSAIDs (tNSAIDs) are effective in treating arthritis pain but can be limited by GI adverse events and general bleeding related to platelet inhibition.…
  • Abstract Number: 0732 • ACR Convergence 2021

    Topical Rofecoxib for OA of the Knee

    Bruce Register1, Nancy Lane2, Lee Simon3, John Newsam4, Edward Kisak4, Jed Pheneger5, John Galvin5, Jeffrey Klein6 and Marc Hochberg7, 1BriOri BioTech, Inc., Newport Beach, CA, 2University of California Davis, Hillsborough, CA, 3SDG LLC, West Newton, MA, 4Tioga Research, Inc, San Diego, CA, 5Inotiv, Boulder, CO, 6Sinclair Research Center, Auxvasse, MO, Canada, 7University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…
  • Abstract Number: 1361 • 2018 ACR/ARHP Annual Meeting

    Predictive Modeling of Therapeutic Response in Knee Osteoarthritis

    Valentina Calamia1, Florencia Picchi1, Ignacio Rego-Pérez2, Maria Camacho1, Lucia González1, Patricia Fernández3, Marta Herrero4, Helena Martinez4, Josep Vergés5, Cristina Ruiz-Romero6 and Francisco J Blanco7, 1Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, 2Rheumatology Research Group, Genomic Unit, INIBIC-CHUAC, A Coruña, Spain, 3Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, 4Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, 5Osteoarthritis Foundation International, Barcelona, Spain, 6Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 7Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain

    Background/Purpose: Phenotype identification in knee osteoarthritis (KOA) population could be useful for predicting drug response, allowing personalized interventions. In order to optimize therapeutic outcome in…
  • Abstract Number: 1434 • 2017 ACR/ARHP Annual Meeting

    COX-2 Inhibitor Contributes Cell Death in Rheumatoid Arthritis Fibroblast-like Synoviocytes Via PI3K/AKT/mTOR Signaling Pathway Triggered By Autophagy

    Sang-Hyon Kim1, Jihye Bang2, Ji-Min Kim1, Chang-Nam Son1, Jin-Nyeong Chae1 and Hye-Jin Jeong3, 1Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, Republic of (South), 3Department of Rheumatology, Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of (South)

    Background/Purpose: Recently, the possibilities that autophagy regulates apoptosis resistance and hyperplasia of fibroblast-like synoviocytes (FLS) were also presented. The aim of this study is to…
  • Abstract Number: 1647 • 2015 ACR/ARHP Annual Meeting

    A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis

    Kara Bickham1, Désirée van der Heijde2, Narinder Rawal3, Joachim Sieper4, Boyd Scott5, Nancy Frontera1, Sandhya Shah1, Paul Stryszak1, Dimitris Papanicolaou1, Zoran Popmihajlov1 and Paul Peloso1, 1Merck & Co., Inc., Kenilworth, NJ, 2University Hospital, Maastricht, Netherlands, 3Orebro University Hospital, Orebro, Sweden, 4Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany, 5Merck Sharp & Dohme Corp., Whitehouse Station, NJ

    Background/Purpose: Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides symptom modification in RA patients. Previous dose-ranging studies in RA demonstrated the clinical efficacy of etoricoxib 90…
  • Abstract Number: 2845 • 2015 ACR/ARHP Annual Meeting

    A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Ankylosing Spondylitis

    Eva Balazcs1, Désirée van der Heijde2, Narinder Rawal3, Joachim Sieper4, Boyd Scott5, Kara Bickham6, Nancy Frontera6, Paul Stryszak6, Dimitris Papanicolaou6, Zoran Popmihajlov6 and Paul Peloso6, 1Department of Neuromusculoskeletal Rehabilitation, Sima F, Szentes, Hungary, 2University Hospital, Maastricht, Netherlands, 3Orebro University Hospital, Orebro, Sweden, 4University Clinic Benjamin Franklin, Berlin, Germany, 5Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 6Merck & Co., Inc., Kenilworth, NJ

     Background/Purpose: Etoricoxib 90 mg, a selective COX-2 inhibitor, provides symptom relief in ankylosing spondylitis (AS) patients. A prior study established etoricoxib 90 mg as safe…
  • Abstract Number: 1141 • 2012 ACR/ARHP Annual Meeting

    Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis

    Rachel E. Sobel1, D. J. Lovell2, Hermine Brunner3, Jennifer E. Weiss4, Paula W. Morris5, Beth S. Gottlieb6, Elizabeth C. Chalom7, Lawrence K. Jung8, Karen Onel9, Lisa Petinoit10, Donald P. Goldsmith11, Staci Abramsky-Risman12, James P., Young13 and Edward H. Giannini14, 1Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Pediatric Rheumatology, Hackensack Univ Med Ctr, Hackensack, NJ, 5Pediatrics, Univ of Arkansas for Med Sci, Little Rock, AR, 6Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 7Pediatrics, St. Barnabas Medical Center, Livingston, NJ, 8Pediatric Rheumatology, Children's National Medical Center, Washington, DC, 9Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 10Pediatric Rheumatology, 'Specially for Children, Dell Children's Medical Center, Austin, TX, 11Pediatric Rheumaology, St Christopher's Hospital for Children/ Drexel College of Medicine, Philadelphia, PA, 12Pfizer Inc, New York, NY, 13United BioSource Corporation, Ann Arbor, MI, 14Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology